Posters
(results will display both Free Papers & Poster)
Congenital cataract management with toric IOL implantation in paediatric cases
Poster Details
First Author: Y.Takhtaev RUSSIA
Co Author(s): E. Panyutina E. Somov S. Takhtaev
Abstract Details
Purpose:
To analyse results of cataract surgery in children with inherital cataract with implantation of different types of Toric IOL.
Setting:
IRTC Fyodorov "Eye Microsurgery" State Institute, Saint-Petersburg branch.
North-Western State Medical University, Saint-Petersburg, Russia
Methods:
15 eyes of 9 patients aged 4-14 years with inherital cataract and corneal astigmatism underwent cataract surgery with primary Toric IOL implantation.
Mean corneal astigmatism in all study groups was 1,78+/-0,44 Dpi. In one cases of Marfan syndrome child presented significant lens subluxation and astigmatism of 3,0 Dpi in both eyes.
Aiming refraction was Hm 1,0 Dpi for patients under 7 y.o. and emmetropia for older patients.
All patients had 2.2 mm phaco aspiration with manual posterior capsulorhexis 4.0 mm diameter before IOL implantation.
AcrySof Toric T3 -T6 and Acrysof Restor Toric T2-T5 models were implanted to correct aphakia.
Results:
All cases were complications free. In group with initial BCVA 0,07+/-0,02 we observed progression of visual function that reached 0,5+/-0,1 BCVA in 1 year follow up.
In group with initial BCVA 0,35+/-0,13 one year post-op results were mean BCVA 0,77+/-0,21. All results were statistically significant.
Using pleoptic treatment after surgery we received stereoscopic vision in all patients.
Residual mean astigmatism in all groups was 0,58+/-0,26 and was statistically significant.
Slit lamp photo method was used to control IOL stability post-op and showed no dislocation from axis in all cases except 1 case with 10 degrees IOL rotation.
Conclusions:
Acrysof Toric and Acrysof Restor Toric IOLs allow to improve visual functions in paediatric cases, correct most of preexisting corneal astigmatism and provide high rotational stability in one year follow-up.
Financial Disclosure:
NONE